




RealRate

PHARMACEUTICAL 2020

Sarepta Therapeutics Inc.
Rank 161 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is -142%, being 161% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,468,913
Cost of Goods Sold	0
Intangible Assets	12,497
Liabilities, Current	264,767
Liabilities, Non-Current	57,968
Other Assets	211,792
Other Compr. Net Income	149
Other Expenses	241,870
Other Liabilities	681,900
Other Net Income	-8,317
Property and Equipment	129,620
Research and Development	560,909
Revenues	380,833
Selling, General and Administrative Expense	284,812

Output Variable	Value in 1000 USD
Assets	1,822,822
Liabilities	1,004,635
Expenses	1,087,591
Stockholders Equity	818,187
Net Income	-715,075
Comprehensive Net Income	-715,000
Economic Capital Ratio	-142%